Mymetics will use its experience in virosome-based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine candidate.
HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.
Ronald Kempers, CEO of Mymetics said the deal “further confirms and recognizes Mymetics as a global leader and niche player in the development and formulation of virosomes and integration of membrane proteins and peptides for immunotherapy and vaccine candidates.”
Dr Nick Ede, Executive Director Imugene added, "Mymetics uses the same vaccine delivery platform for infectious diseases that we are using for our immuno-oncology program and together both companies will work to exploit the potential value of influenza-based virosomes.”
On top of the manufacturing deal, Mymetics currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal influenza, malaria, herpes simplex virus and the RSV vaccine. The HIV-1 vaccine has completed a Phase I trial in healthy human volunteers. A Phase Ib clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase.